A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMIDE (LEN) IN RELAPSED AND REFRACTORY (R/R) CUTANEOUS (CTCL) AND PERIPHERAL (PTCL) T‐CELL LYMPHOMAS: PRELIMINARY RESULTS OF A PHASE II TRIAL. (12th June 2019) - William, B.M.